UCB
Also known as: 0018445992273 | 001 844 599 22733 (UCB) | 001 844 599 2273 (UCB) | +1 844 599 2273 (UCB) | +1-844-599-2273 (UCB) | 1-844-599-2273(UCB) | +1 877 822 9493 (UCB) | 1 877 822 9493 (UCB) | 1-877-822-9493 (UCB) | UCB (+1 844 599 2273) | UCB (+1 877 822 9493) | UCB (+1 887 822 9493) | UCB Biopharma S.P.R.L. | UCB Biopharma SRL | UCB BIOSCIENCES, Inc. | UCB Celltech | UCB / Global Medical Affairs | UCB, Inc. | UCB INC | UCB Japan Co. Ltd. | UCB Nordic A/S | UCB Pharma | UCB Pharma GmbH | UCB Pharma SA | UCB S.A. - Pharma Sector | UCB Trading (Shanghai) Co. Ltd. | UCB Young Investigator Research Program | WHITBY
Highest phase reached
Phase 4
First clinical trial
Jan 31, 2012First marketed drug
Sep 9, 1955First NDA
Sep 9, 1955Last known activity
Dec 31, 2025
Timeline
1920s
- Jan 1, 1928
UCB— Founded
1980s
- Jun 19, 1987
pseudoephedrine— NDA Secondary Org
2000s
- Jan 1, 2004
Celltech— Acquired
- Aug 27, 2004
levodopa— Marketing Organization
- Jan 1, 2006
Schwarz Pharma— Acquired
- May 25, 2007
levocetirizine— NDA Organization
2010s
- Oct 10, 2019
Ra Pharmaceuticals— Acquired
2020s
- Jun 5, 2020
Engage Therapeutics Inc.— Acquired - Jan 20, 2022
Zogenix, Inc.— Acquired
Drugs by trial phase (58 distinct, 208 trials)
Phase 4 (2 own, 5 via acquisition)
Phase 3 (11 own, 7 via acquisition)
Phase 2 (9 own, 6 via acquisition)
Phase 1 (15 own, 3 via acquisition)
Indications
Approved for
Studied for
- Alzheimer Disease
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Crohn Disease
- Dermatitis
- Dermatitis, Atopic
- Drug Resistant Epilepsy
- Eczema
- Epilepsy
- Epilepsy, Absence
- Epilepsy, Reflex
- Hidradenitis
- Hidradenitis Suppurativa
- Lupus Erythematosus, Systemic
- Muscle Weakness
- Myasthenia Gravis
- Neoplasm Metastasis
- Neoplasms
- Paralysis
- Parkinson Disease
- Polyradiculoneuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Psoriasis
- Psychomotor Agitation
- Purpura, Thrombocytopenic, Idiopathic
- Respiratory Insufficiency
- Restless Legs Syndrome
- Seizures
- Spondylarthritis
- Spondylitis
- Spondylitis, Ankylosing
- Supranuclear Palsy, Progressive
- Syndrome
- Thrombocytopenia
- Urticaria
- Wounds and Injuries
Marketed drugs (36)
Subsidiaries (5 direct, 14 total across the full acquisition tree)
Recent trials (50)
- NCT03559686Study directorN/A—
- NCT03532516Lead sponsorN/A—
- NCT05014724Lead sponsorN/A—
- NCT06590493Lead sponsorN/A—
- NCT05014724Study directorN/A—
- NCT03559660Lead sponsorN/A—
- NCT03559673Lead sponsorN/A—
- NCT03559686Lead sponsorN/A—
- NCT03559660Study directorN/A—
- NCT07246564OfficialPhase 4Dec 31, 2025
- NCT07277660Lead sponsorPhase 2Dec 31, 2025
- NCT07290036Lead sponsorPhase 1Dec 31, 2025
- NCT07246564Lead sponsorPhase 4Dec 31, 2025
- NCT07290036OfficialPhase 1Dec 31, 2025
- NCT07286682OfficialPhase 1Dec 8, 2025
Details
- Founded
- Brussels, BE Jan 1, 1928
- First NDA
- Sep 9, 1955
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Priority review